A 28-year-old woman with newly diagnosed pulmonary tuberculosis is found to be resistant to isoniazid and rifampicin on drug susceptibility testing. She has no history of prior TB treatment. What is the drug of choice for initiating second-line therapy in this patient with MDR-TB (multidrug-resistant tuberculosis)?

Explanation

## Second-Line Therapy for MDR-TB **Key Point:** Bedaquiline is a novel ATP synthase inhibitor and is now the **preferred first-line agent for MDR-TB** according to WHO 2019 guidelines and Indian TB treatment guidelines. It has replaced fluoroquinolones as the cornerstone of MDR-TB regimens. **High-Yield:** The shift from fluoroquinolone-based to bedaquiline-based MDR-TB regimens represents a major paradigm change in TB treatment. Bedaquiline has superior efficacy, faster sputum conversion, and better outcomes compared to older second-line agents. ### MDR-TB Treatment Regimen (Current WHO/India Guidelines) **Bedaquiline-based regimen (preferred):** - **Bedaquiline** (ATP synthase inhibitor) — backbone - **Fluoroquinolone** (levofloxacin or moxifloxacin) — for drug-susceptible TB or as adjunct - **Linezolid** (in selected cases) - **Pyrazinamide** (if susceptible) - **Ethambutol** (if susceptible) - **Ethionamide or prothionamide** (injectable second-line agent alternative) ### Comparison of Second-Line Agents | Agent | Mechanism | Efficacy in MDR-TB | Toxicity Concerns | Role | | --- | --- | --- | --- | --- | | **Bedaquiline** | ATP synthase inhibitor | **Highest** — 70–80% cure | QT prolongation; hepatotoxicity | **First-choice backbone** | | **Fluoroquinolone** | DNA gyrase inhibitor | Moderate — 40–50% | GI upset; tendinitis | Adjunctive (no longer backbone) | | **Linezolid** | Protein synthesis inhibitor | Good — 60–70% | Peripheral neuropathy; bone marrow suppression | Reserved for resistant/intolerant cases | | **PAS** | PABA antagonist | Weak — 30–40% | GI intolerance; crystalluria | Adjunctive only | **Clinical Pearl:** Bedaquiline is a game-changer in MDR-TB because it: - Achieves faster sputum conversion (median 2 months vs. 4–5 months with fluoroquinolones) - Improves cure rates from ~50% to ~70–80% - Has bactericidal activity against both actively dividing and dormant bacilli - Penetrates macrophages and caseous lesions effectively **Warning:** Bedaquiline can prolong QT interval — baseline ECG and electrolyte monitoring are mandatory. Avoid concurrent QT-prolonging drugs (including fluoroquinolones in some cases). **Mnemonic:** **B**edaquiline = **B**ackbone of modern MDR-TB therapy. ### Why Bedaquiline Is the Correct Answer Bedaquiline is now the **preferred first-line agent for MDR-TB** because: 1. Superior bactericidal activity and faster sputum conversion 2. Better treatment outcomes (70–80% vs. 50% with fluoroquinolone-based regimens) 3. WHO and Indian TB guidelines (2019 onwards) recommend bedaquiline-based regimens 4. It is the only agent among the options with proven superiority in MDR-TB [cite:Harrison 21e Ch 158; WHO TB Guidelines 2019]